26 Feb 15
Wragge Lawrence Graham & Co's Corporate team has advised longstanding client and AIM-quoted Ambrian plc on its merger with Consolidated General Minerals plc (CGM).
26 Feb 15
Argent and its partner Related will be recommended to Barnet Council's key regeneration committee as the Council's long term development partner on the 78 hectare Brent Cross South scheme. Argent is best known in London for its work on the redevelopment of King's Cross.
25 Feb 15
Wragge Lawrence Graham & Co's life sciences experts have advised long-standing client AstraZeneca on a drug discovery collaboration agreement with Orca Pharmaceuticals.
23 Feb 15
Wragge Lawrence Graham & Co's Investment Funds team has advised Gabelli Value Plus+ Trust Plc (Gabelli Value Plus) on a fundraising worth £100 million.
20 Feb 15
Wragge Lawrence Graham & Co's Investment Funds team has acted on two significant real estate funds transactions within the space of a month.
19 Feb 15
Wragge Lawrence Graham & Co's Private Equity team in Paris has advised longstanding client Société Générale Capital Partners, in partnership with Sagard and Euromezzanine, on the leveraged buyout of specialty chemicals distributor Safic-Alcan from Parquest Capital.
18 Feb 15
Wragge Lawrence Graham & Co has led the London Borough of Croydon to success in a vital Court of Appeal case concerning "Zambrano carers" and their right to receive social assistance.
17 Feb 15
Wragge Lawrence Graham & Co has reaffirmed its public sector credentials with an appointment to the national legal services procurement framework for Local Government Pension Scheme (LGPS) Funds.
16 Feb 15
Derwent London plc has exchanged contracts with LaSalle Investment Management ("LaSalle"), the global real estate investment manager, to acquire a minimum 175-year long leasehold of 20 Farringdon Road, Clerkenwell EC1 in London’s Tech Belt. LaSalle will retain the building’s virtual freehold with the right to receive 10% of all rents.
11 Feb 15
Wragge Lawrence Graham & Co's Life Sciences team has advised GlaxoSmithKline (GSK) on the sale of its shareholding interests in biopharmaceutical company Convergence Pharmaceuticals to NASDAQ-listed Biogen Idec. The $675 million deal takes place just four years after the team advised GSK on the spin-out venture which created Convergence.